Buprenorphine Dosing for Kratom Withdrawal
For kratom withdrawal, initiate buprenorphine/naloxone at 4-8 mg/day for patients using less than 20 grams of kratom daily, or 12-16 mg/day for those using more than 40 grams daily, with induction starting 8-12 hours after last kratom use.
Evidence-Based Dosing Strategy
The most robust evidence comes from a 2021 systematic review and case series demonstrating a strong correlation (r=0.84) between daily kratom dose and required buprenorphine/naloxone dose 1. This provides the clearest dosing framework:
Initial Dosing Algorithm
Low kratom users (<20 g/day):
- Start with 4-8 mg buprenorphine/naloxone on day 1
- This represents the 4/1 mg to 8/2 mg formulation
High kratom users (>40 g/day):
- Start with 12-16 mg buprenorphine/naloxone on day 1
- This represents the 12/3 mg to 16/4 mg formulation
Moderate users (20-40 g/day):
- Start with 8-12 mg buprenorphine/naloxone
- Titrate based on Clinical Opiate Withdrawal Scale (COWS) scores
Timing of Induction
Begin induction 8-12 hours after last kratom use 2. Unlike traditional opioids, kratom's partial agonist properties make precipitated withdrawal less likely, allowing for earlier induction than the typical requirement for full opioid agonists 3.
Maintenance Dosing
The largest case series (n=28) found that most patients stabilize on 8-16 mg/day regardless of their initial kratom dose 4. Specifically:
- 82% of patients (23/28) stabilized between 8-16 mg daily
- Some patients with severe withdrawal or co-occurring pain required up to 24 mg/day in divided doses 2
- Average maintenance duration was 11 months with 82% achieving negative mitragynine tests by 12 weeks 4
Maintenance Strategy
- Target dose: 12-16 mg/day (consistent with FDA labeling for opioid use disorder) 3
- Adjust in 2-4 mg increments based on withdrawal symptoms and cravings
- Consider divided dosing (every 6-8 hours) for patients with persistent withdrawal symptoms 2
Critical Clinical Considerations
Induction Pitfalls
Do not wait for severe withdrawal before initiating buprenorphine. Kratom withdrawal typically presents with COWS scores of 10-14 5, but you can safely induce at COWS ≥8 given kratom's partial agonist profile.
Home induction is feasible for kratom withdrawal, unlike traditional opioid use disorder 6. Two patients successfully completed unobserved home induction with telehealth follow-up, though this requires careful patient selection and close monitoring.
Withdrawal Timeline
Expect prolonged withdrawal symptoms despite adequate buprenorphine dosing 2. Kratom's unique alkaloid profile (mitragynine and 7-hydroxymitragynine) may produce withdrawal symptoms that persist longer than typical opioid withdrawal, requiring extended treatment duration.
Polysubstance Use
Patients with concurrent substance use disorders may require:
- Higher buprenorphine doses (up to 20-24 mg/day)
- Higher levels of care (residential vs. outpatient)
- More intensive monitoring 2
Monitoring and Adjustment
Urine drug screening for mitragynine is essential 2, 4. Standard opioid panels will not detect kratom alkaloids. Facilities treating kratom dependence should have specific kratom testing available.
Expect individual variability: Two patients using identical kratom doses (35 g/day) stabilized on significantly different buprenorphine maintenance doses 6, suggesting that duration of use and psychological factors influence optimal dosing beyond just quantity consumed.
Special Populations
For medically complex patients, be aware that kratom inhibits cytochrome P450 enzymes and P-glycoprotein 7, potentially causing drug interactions. Monitor closely when patients are on medications metabolized through these pathways.
For patients with co-occurring psychiatric disorders (anxiety, depression, OCD), low-dose buprenorphine (as low as 2-8 mg/day) may be sufficient when combined with appropriate psychiatric management 8, though this represents the lower end of the dosing spectrum.
Treatment Duration
Plan for long-term maintenance rather than short-term detoxification. The case series data shows patients remaining in treatment for 5-22 months (average 11 months) with good outcomes 4. One patient successfully tapered to 0.25 mg before self-discharge 4, but most require extended maintenance similar to traditional opioid use disorder treatment.